Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […]
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […]
